Drugs / AAVAnc80-hOTOF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05821959 | Sep 2023 → Oct 2028 expected | sensorineural hearing loss disorder | Akouos, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-01-23 | Eli Lilly and Company | Results Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting lilly.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-01-23 | Eli Lilly and Company | Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting lilly.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAVAnc80-hOTOF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05821959 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “A Trial of AAVAnc80-hOTOF Gene Therapy in Individuals With Sensorineural Hearing Loss Due to Otoferlin Gene Mutations” NCT05821959 ↗ |
| Route | Other | “intracochlear administration” NCT05821959 ↗ |